Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Suzhou Zelgen Biopharmaceuticals Co's revenue for the
three
months ended in Jun. 2026 was ¥300 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was ¥1,640 Mil.
Suzhou Zelgen Biopharmaceuticals Co's Revenue per Share for the
three
months ended in Jun. 2026 was ¥1.14.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was ¥6.20.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Suzhou Zelgen Biopharmaceuticals Co Revenue Related Terms
Suzhou Zelgen Biopharmaceuticals Co Revenue Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688266 vs VRTX, REGN, MRNA: Revenue Comparison
For the Biotechnology subindustry, Suzhou Zelgen Biopharmaceuticals Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Suzhou Zelgen Biopharmaceuticals Co Revenue vs Biotechnology Industry
Suzhou Zelgen Biopharmaceuticals Co Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,640 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) has a Revenue of ¥1,640 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Suzhou Zelgen Biopharmaceuticals Co and its competitors.
Is Suzhou Zelgen Biopharmaceuticals Co's Revenue too high?
Suzhou Zelgen Biopharmaceuticals Co's current Revenue is ¥1,640 Mil. Overall, Suzhou Zelgen Biopharmaceuticals Co has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Suzhou Zelgen Biopharmaceuticals Co's Revenue compare to VRTX and REGN?
Suzhou Zelgen Biopharmaceuticals Co's Revenue of ¥1,640 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Suzhou Zelgen Biopharmaceuticals Co and its competitors. Suzhou Zelgen Biopharmaceuticals Co's current Revenue is ¥1,640 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suzhou Zelgen Biopharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥223.13, compared to a current price of ¥109.10 — trading 51.1% below its estimated fair value. The current Revenue is ¥1,640 Mil. Suzhou Zelgen Biopharmaceuticals Co's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266), the current Revenue is ¥1,640 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Overvalued in 2026?
Based on GuruFocus' analysis, Suzhou Zelgen Biopharmaceuticals Co stock appears to be undervalued.
The current stock price of ¥109.10 is trading 51.1% below its estimated GF Value™ of ¥223.13.
GuruFocus considers Suzhou Zelgen Biopharmaceuticals Co to be Significantly Undervalued.
Key valuation signals for SHSE:688266:
Revenue: ¥1,640 Mil
GF Value™: ¥223.13 vs. price of ¥109.10 (51.1% below fair value)
No single metric tells the full story. See the SHSE:688266 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Suzhou Zelgen Biopharmaceuticals Co Ltd is engaged in research and development of new chemical and biological drugs for various therapeutic areas, including tumors, bleeding and blood diseases, and hepatobiliary diseases.
69GF Score
Get the complete analysis for SHSE:688266
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688266 has been successfully added to your 
